期刊
MOLECULAR ONCOLOGY
卷 9, 期 10, 页码 2043-2053出版社
WILEY
DOI: 10.1016/j.molonc.2015.10.009
关键词
Cancer; Immunotherapy; Personalized; T cells; Immune checkpoint
类别
资金
- Leukemia and Lymphoma Society [P-QFC-3068-14]
- National Institutes of Health [R01CA155143]
- Cancer Prevention and Research Institute of Texas [RP150316]
- University of Texas MD Anderson Cancer Center's Moon Shots Program
The results of recent clinical trials using novel immunotherapy strategies such as immune checkpoint blockade and adoptive T-cell therapy approaches including CAR T-cell therapy have clearly established immunotherapy as an important modality for the treatment of cancer besides the traditional approaches of surgery, radiotherapy, and chemotherapy or targeted therapy. However, to date immunotherapy has been shown to induce durable clinical benefit in only a fraction of the patients. The use of combination strategies is likely to increase the number of patients that might benefit from immunotherapy. Indeed, over the last decade, the characterization of multiple immune resistance mechanisms used by the tumor to evade the immune system and the development of agents that target those mechanisms has generated a lot of enthusiasm for cancer immunotherapy. But a critical issue is to determine how best to combine such agents. This review will focus on novel immunotherapy agents currently in development and discuss strategies to develop and personalize combination cancer immunotherapy strategies. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据